Drugs / Asparaginase (E. coli)
Asparaginase (E. coli)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00165087 | Jan 1996 → Sep 2006 | childhood acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Terminated | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00002471 Background | Feb 1990 → Jan 2003 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Asparaginase (E. coli) | “Asparaginase (E. coli), ASP, NSC-109229” NCT00002471 ↗ |
| Known as | ASP | “Asparaginase (E. coli), ASP, NSC-109229” NCT00002471 ↗ |
| Known as | NSC-109229 | “Asparaginase (E. coli), ASP, NSC-109229” NCT00002471 ↗ |